Cite
HARVARD Citation
Schouten, P. et al. (n.d.). BRCA1‐like profile predicts benefit of tandem high dose epirubicin‐cyclophospamide‐thiotepa in high risk breast cancer patients randomized in the WSG‐AM01 trial. International journal of cancer. 139 (4), pp. 882-889. [Online].